Last updated on October 2017

A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.


Brief description of study

A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.

Detailed Study Description

This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who are anti-tumor necrosis factor (TNF) naive (TNF-naive) and in patients who are refractory or intolerant of tumor necrosis factor inhibitors.

Clinical Study Identifier: TX153721

Find a site near you

Start Over

Gastro Florida

3001 Executive Dr suite 130 Clearwater, FL USA
7.65miles
  Connect »